Prostate Cancer: Personal Stories of Early Detection and Survival

Prostate cancer remains one of the most prevalent malignancies among men in the United States, affecting one in eight men during their lifetime. According to estimates from the American Cancer Society, approximately 300,000 new cases were expected to be diagnosed in 2024, with more than 35,000 deaths anticipated from the disease.

The disease often presents a silent risk because early-stage (stage I) prostate cancer frequently produces no symptoms. This lack of early indicators makes routine screening critical, as symptoms typically only emerge when the cancer has reached an advanced stage, which can make the disease more difficult to cure.

The Role of Screening and Early Detection

Screening often involves the prostate-specific antigen (PSA) test, a blood test used to monitor levels that may indicate the presence of cancer. For some patients, consistent monitoring over decades can reveal sudden shifts in these levels that prompt further investigation.

View this post on Instagram

In one case, Jesse Bennett, a resident of Baltimore, had his PSA levels monitored starting in his early 40s. For two decades, his levels remained consistent, averaging around 2.0. However, in 2009, when Bennett was 62, a higher PSA result led his doctor to recommend a prostate biopsy.

The biopsy revealed an aggressive type of cancer. Doctors assigned the cancer a Gleason score of 8 out of 10. The Gleason score is used to grade prostate cancer based on the appearance of cells under a microscope, helping clinicians predict how quickly the cancer might grow or spread. Scores between 8 and 10 are categorized as poorly differentiated or high-grade.

Treatment Paths and Patient Outcomes

Treatment strategies vary based on the grade and stage of the cancer. For high-grade tumors, such as those with a Gleason score of 8, surgeons may recommend a radical prostatectomy, which is the surgical removal of the entire prostate gland.

Following a radical prostatectomy, some patients see their PSA levels return to an undetectable state. In the case of Jesse Bennett, the surgery left no detectable sign of cancer and his doctors determined that radiation or chemotherapy was not recommended.

Other patients face the disease at much later stages. Steven Daniel was diagnosed with stage 4 prostate cancer in 2017 after experiencing escalating chest and back pain, which led to hospitalization during an Easter weekend. His journey included treatment through a clinical trial.

Long-Term Survival and Resilience

Survivorship and long-term health management are central to the experience of those living with prostate cancer. Brian Peters, who has been cancer-free for five years, celebrated this milestone by completing the Los Angeles Marathon, running 26.2 miles to promote resilience and early detection as he approached his 65th birthday.

The importance of continued vigilance is highlighted by patients who experience recurrence. Jesse Bennett remained vigilant with follow-up exams and PSA testing for 13 years following his 2009 diagnosis, maintaining undetectable PSA levels of less than 0.1 until November 2020, when a routine follow-up indicated a change.

Public health advocates and survivors, such as Robert Ginyard, continue to urge men to undergo early screening to save lives through increased awareness and research.

Clinical Context of Prostate Cancer

The prostate is a small gland in the male reproductive system essential for producing seminal fluid. In a healthy state, It’s shaped similarly to a walnut. Cancer occurs when cells within this gland begin to multiply uncontrollably.

While some forms of prostate cancer progress slowly and may not cause significant harm, aggressive forms can spread rapidly. Medical professionals emphasize that screenings are becoming less invasive and less painful over time to encourage more men to seek early detection.